A master cancer gene hijacks a ‘molecular crowbar’ to make breast cancer cells invasive January 22, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
A master cancer gene hijacks a ‘molecular crowbar’ to make breast cancer cells invasive January 22, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
Conferences Phase II trial shows neurocognitive function decline but stable quality of life in first year after temozolomide-based chemoradiotherapy November 28, 2019 A secondary analysis of the phase II clinical trial NRG-RTOG 0424, which initially reported a 73.1%…